Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Reported Tuberculosis in the United States, 2021						Print
																Related Pages
										Return to Main Menu
Table 50. Number and Percentage1 of Persons with TB Disease who Completed Therapy Within 1 Year: Reporting Areas, 2015–20192
Number and percentage of persons with tuberculosis disease who completed therapy within one year by reporting area.
Reporting area
2015
2016
2017
2018
2019Total cases3
Completed therapy
Total cases3
Completed therapy
Total cases3
Completed therapy
Total cases3
Completed therapy
Total cases3
Completed therapyNo.
(%)
No.
(%)
No.
(%)
No.
(%)
No.
(%)United States4
7,852
7,083
(90.2)
7,575
6,768
(89.3)
7,394
6,686
(90.4)
7,355
6,574
(89.4)
7,189
6,460
(89.9)Alabama
98
85
(86.7)
97
85
(87.6)
107
95
(88.8)
81
70
(86.4)
71
66
(93.0)Alaska
59
55
(93.2)
54
48
(88.9)
47
43
(91.5)
57
54
(94.7)
52
47
(90.4)Arizona
150
139
(92.7)
135
118
(87.4)
146
135
(92.5)
135
114
(84.4)
116
109
(94.0)Arkansas
79
67
(84.8)
70
55
(78.6)
76
60
(78.9)
71
54
(76.1)
56
49
(87.5)California
1,763
1,570
(89.1)
1,647
1,456
(88.4)
1,661
1,498
(90.2)
1,712
1,512
(88.3)
1,696
1,499
(88.4)Colorado
61
58
(95.1)
46
41
(89.1)
68
62
(91.2)
58
56
(96.6)
55
52
(94.5)Connecticut
56
53
(94.6)
41
40
(97.6)
49
48
(98.0)
43
43
(100.0)
53
49
(92.5)Delaware
18
16
(88.9)
14
14
(100.0)
9
9
(100.0)
17
14
(82.4)
16
13
(81.3)District of Columbia
24
21
(87.5)
19
18
(94.7)
30
23
(76.7)
27
25
(92.6)
22
19
(86.4)Florida
495
474
(95.8)
535
498
(93.1)
454
432
(95.2)
501
487
(97.2)
467
455
(97.4)Georgia
269
243
(90.3)
244
217
(88.9)
240
207
(86.3)
222
206
(92.8)
251
226
(90.0)Hawaii
113
108
(95.6)
102
101
(99.0)
97
94
(96.9)
101
95
(94.1)
86
79
(91.9)Idaho
9
9
(100.0)
15
14
(93.3)
9
8
(88.9)
8
6
(75.0)
6
6
(100.0)Illinois
289
273
(94.5)
275
252
(91.6)
272
250
(91.9)
257
229
(89.1)
242
225
(93.0)Indiana
101
95
(94.1)
91
84
(92.3)
84
81
(96.4)
96
92
(95.8)
90
85
(94.4)Iowa
34
29
(85.3)
40
37
(92.5)
39
38
(97.4)
42
40
(95.2)
39
30
(76.9)Kansas
32
30
(93.8)
37
34
(91.9)
20
20
(100.0)
23
23
(100.0)
26
26
(100.0)Kentucky
53
50
(94.3)
77
74
(96.1)
49
48
(98.0)
47
40
(85.1)
50
48
(96.0)Louisiana
106
85
(80.2)
112
85
(75.9)
119
99
(83.2)
91
69
(75.8)
76
56
(73.7)Maine
15
15
(100.0)
21
20
(95.2)
9
9
(100.0)
13
11
(84.6)
16
14
(87.5)Maryland
141
128
(90.8)
182
170
(93.4)
172
149
(86.6)
173
134
(77.5)
176
147
(83.5)Massachusetts
151
134
(88.7)
156
138
(88.5)
168
159
(94.6)
168
141
(83.9)
142
121
(85.2)Michigan
112
107
(95.5)
115
109
(94.8)
99
95
(96.0)
85
81
(95.3)
105
100
(95.2)Minnesota
125
119
(95.2)
138
130
(94.2)
138
132
(95.7)
139
128
(92.1)
114
102
(89.5)Mississippi
55
49
(89.1)
47
42
(89.4)
43
37
(86.0)
65
61
(93.8)
49
44
(89.8)Missouri
77
63
(81.8)
90
73
(81.1)
72
53
(73.6)
66
49
(74.2)
62
49
(79.0)Montana
7
7
(100.0)
4
4
(100.0)
3
3
(100.0)
3
3
(100.0)
1
0
(0.0)Nebraska
27
10
(37.0)
25
14
(56.0)
15
10
(66.7)
24
19
(79.2)
13
11
(84.6)Nevada
70
67
(95.7)
43
41
(95.3)
66
65
(98.5)
58
58
(100.0)
41
40
(97.6)New Hampshire
7
7
(100.0)
10
10
(100.0)
17
15
(88.2)
10
10
(100.0)
6
6
(100.0)New Jersey
253
230
(90.9)
242
227
(93.8)
212
197
(92.9)
229
211
(92.1)
251
233
(92.8)New Mexico
29
27
(93.1)
28
25
(89.3)
25
24
(96.0)
34
31
(91.2)
37
33
(89.2)New York State5
149
140
(94.0)
160
153
(95.6)
161
150
(93.2)
141
135
(95.7)
137
121
(88.3)New York City
489
460
(94.1)
447
417
(93.3)
494
459
(92.9)
447
416
(93.1)
458
413
(90.2)North Carolina
162
150
(92.6)
189
172
(91.0)
185
175
(94.6)
170
147
(86.5)
165
148
(89.7)North Dakota
7
6
(85.7)
21
19
(90.5)
13
12
(92.3)
11
9
(81.8)
12
9
(75.0)Ohio
116
97
(83.6)
118
91
(77.1)
123
103
(83.7)
149
129
(86.6)
127
109
(85.8)Oklahoma
59
52
(88.1)
59
56
(94.9)
48
46
(95.8)
58
55
(94.8)
52
43
(82.7)Oregon
65
57
(87.7)
58
46
(79.3)
61
55
(90.2)
70
67
(95.7)
62
60
(96.8)Pennsylvania
165
134
(81.2)
139
109
(78.4)
156
118
(75.6)
173
146
(84.4)
144
129
(89.6)Rhode Island
23
23
(100.0)
8
7
(87.5)
9
7
(77.8)
14
11
(78.6)
11
8
(72.7)South Carolina
86
79
(91.9)
83
78
(94.0)
87
80
(92.0)
61
57
(93.4)
60
57
(95.0)South Dakota
14
7
(50.0)
9
8
(88.9)
11
11
(100.0)
11
8
(72.7)
12
11
(91.7)Tennessee
106
101
(95.3)
86
82
(95.3)
105
100
(95.2)
108
100
(92.6)
112
109
(97.3)Texas
1,088
951
(87.4)
1,042
885
(84.9)
902
772
(85.6)
907
778
(85.8)
940
814
(86.6)Utah
31
29
(93.5)
18
17
(94.4)
24
23
(95.8)
13
13
(100.0)
22
21
(95.5)Vermont
7
7
(100.0)
5
5
(100.0)
2
1
(50.0)
5
2
(40.0)
4
3
(75.0)Virginia
180
166
(92.2)
172
159
(92.4)
176
171
(97.2)
168
158
(94.0)
161
151
(93.8)Washington
161
145
(90.1)
164
152
(92.7)
167
156
(93.4)
152
143
(94.1)
180
169
(93.9)West Virginia
6
5
(83.3)
11
9
(81.8)
13
11
(84.6)
5
3
(60.0)
6
6
(100.0)Wisconsin
58
49
(84.5)
34
29
(85.3)
40
36
(90.0)
35
30
(85.7)
40
39
(97.5)Wyoming
2
2
(100.0)
0
0
...
2
2
(100.0)
1
1
(100.0)
1
1
(100.0)American Samoa
4
0
(0.0)
1
0
(0.0)
5
0
(0.0)
2
1
(50.0)
1
0
(0.0)Federated States of Micronesia
93
84
(90.3)
124
119
(96.0)
129
122
(94.6)
98
89
(90.8)
76
66
(86.8)Guam
66
63
(95.5)
66
56
(84.8)
74
68
(91.9)
62
53
(85.5)
73
65
(89.0)Republic of the Marshall Islands
118
103
(87.3)
157
90
(57.3)
179
89
(49.7)
387
286
(73.9)
213
174
(81.7)Northern Mariana Islands
26
21
(80.8)
25
23
(92.0)
39
37
(94.9)
41
37
(90.2)
44
41
(93.2)Puerto Rico
38
28
(73.7)
52
46
(88.5)
30
22
(73.3)
19
15
(78.9)
26
26
(100.0)Republic of Palau
11
10
(90.9)
19
16
(84.2)
16
15
(93.8)
11
10
(90.9)
6
6
(100.0)U.S. Virgin Islands
0
0
...
0
0
...
4
1
(25.0)
1
0
(0.0)
1
0
(0.0)Show More1Among persons for whom completion of therapy ≤1 year was indicated.2Most recent year for which data are complete.3Persons alive at diagnosis with an initial regimen of one or more drugs prescribed who did not die within one year of initiating therapy. Excludes persons with an initial isolate resistant to rifampin, or persons with bone and joint disease, meningeal disease or disease of the central nervous system, or persons <15 years of age with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and persons who moved out of the country within one year of initiating treatment.4American Samoa, Federated States of Micronesia, Guam, Republic of the Marshall Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands are not included in the U.S. totals and percentages.5Excludes New York City.
**Note:**
Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
See Technical Notes.Table Printing Tips
							
					
							Last Reviewed:  November 29, 2022						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue